Summary:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
Qualified Participants Must:
• Aged 18 years or older at the time of informed consent
• Fasting TG greater than or equal to 500 mg/dL (5.65 mmol/L) at both the Run-in Period and the Qualification Period
• Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines
Qualified Participants May Receive:
Participants in this study will receive medical care, undergo liver MRI treatment, and receive approximately $1700 as compensation.